Continuing Research for a Colon Cancer Vaccine

Everyone reading this likely has received a vaccine of some kind, such as one for polio, flu or measles. For those affected by colon cancer, a vaccine for the disease may seem like a far-fetched dream, but maybe it isn’t. News from the world of cancer vaccine research is very encouraging—colon cancer vaccines are being studied at several major research centers and the early results look promising.

Cancer vaccines, in general, are nothing new, of course. They typically fall into one of two categories: preventive and treatment.  Preventive vaccines prevent cancer from developing in healthy people. These are similar to the traditional vaccines most of us have had.

Two preventive cancer vaccines that have been approved by the U.S. Food and Drug Administration (FDA) are Gardasil® and Cervarix®, which protect against infection from the virus that can cause cervical cancer. You have likely seen advertisements for these vaccines. Another preventive vaccine protects against hepatitis B (HBV) infection, which can lead to liver cancer. Most children in the United States receive this vaccine shortly after birth.

Treatment vaccines treat an existing cancer by strengthening the body’s natural defenses against the cancer. Only one cancer treatment vaccine has been approved by the FDA. Provenge® is used to treat some men who have metastatic prostate cancer (cancer that has spread to other parts of the body).

In September, Susie’s Cause made a donation to the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins to fund research for a colon cancer vaccine. The team at Hopkins recently completed a phase 1 clinical trial of a vaccine. Their new study will test a combination vaccine therapy in advanced colorectal cancer patients who have completed chemotherapy. If successful, this treatment would give patients a way to keep their disease stable after treatment and could prove to be helpful in earlier stages of the disease as well. 

Other colon cancer vaccine studies are taking place at Thomas Jefferson University in Philadelphia and Georgetown University Medical Center in Washington, D.C. The University of Pittsburgh Cancer Institute announced initial success of their colon cancer vaccine in human trials earlier this year. Their study, published in the January 2013 edition of Cancer Prevention Research, showed that their vaccine is safe and produced the immune response they expected.

These are exciting times in cancer research! The Susan Cohan Colon Cancer Foundation will be watching to see how these studies unfold. Be sure to check our website (www.coloncancerfoundation.org) and like our page on Facebook for the latest developments.